SELLAS Life Sciences Group, Inc. (SLS) News & Overview - Discounting Cash Flows
SLS
SELLAS Life Sciences Group, Inc.
SLS (NASDAQ)

SLS's Business Model

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Sector & Industry Healthcare / Biotechnology
Website https://www.sellaslifesciences.com
CEO (Chief Executive Officer) Angelos M. Stergiou ScD h.c.
Number of Employees
IPO date March 12, 2008

SLS Latest News

Contact
CountryUS
AddressTimes Square Tower
CityNew York City
StateNY
Phone646 200 5278
Zip Code10036
Other Identifiers
CIK0001390478
ISINUS81642T2096
CUSIP81642T209
Open1.87
Previous Close1.895
Volume1.78 Mil.
Average Volume2.87 Mil.
Day’s Range1.83 – 1.905
52 Week Range0.77-2.27
MA (50)1.7436
MA (200)1.31575
Market Cap183.6 Mil.
Shares Out.99.78 Mil.
Earnings DateAug 14, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for SLS

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us